November 9, 2018 — Wearable cardiac biosensor developer Cardiac Insight Inc. has partnered with VivoSense, specializing in integration and specialized analysis of wearable sensor data for research and clinical trials. Together, both companies will deliver enhanced research analytics to help VivoSense expand the use of wearable biosensors for pharmaceutical clinical trials and other healthcare applications.
Sophisticated new analytics are the key to making sense of the complex data sets generated by human study participants in response to new drug candidates and genetics-driven population health research, according to Dudley Tabakin, CEO and co-founder of VivoSense. The collaboration between the two companies will use the Cardiac Insight Cardea Solo electrocardiogram (ECG) sensor data with VivoSense software, data cleaning, robust analytics and regulatory-compliant biomarkers.
VivoSense ingests data from many different wearable sensors, from high-resolution cardiorespiratory and other cardiac sensors like Cardea Solo to wrist-worn activity trackers. This data from on-body sensors is integrated, cleaned and synchronously analyzed with robust algorithms and scientific oversight from the VivoSense platform.
Comfortable and unobtrusive wearable cardiorespiratory sensors are finding ubiquitous use in sports and fitness research, longitudinal healthcare monitoring and in regulated clinical trials. The very large physiological data sets generated by these sensors are the key to monitoring health and providing a greater understanding of the effects of new medicines and therapies, according to the companies.
For more information: www.cardiacinsightinc.com, www.vivosense.com
August 15, 2024 
